Coronavirus disease 2019 in immunocompromised patients: a comprehensive review of coronavirus disease 2019 in hematopoietic stem cell recipients.
Journal
Current opinion in critical care
ISSN: 1531-7072
Titre abrégé: Curr Opin Crit Care
Pays: United States
ID NLM: 9504454
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
24
11
2021
medline:
31
12
2021
entrez:
23
11
2021
Statut:
ppublish
Résumé
Immunocompromised patients are notably vulnerable to severe coronavirus disease 2019. This review summarizes COVID-19 features and outcomes in autologous and allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Recent findings suggest that HSCT recipients exhibit a high burden of comorbidities and COVID-19 clinical features almost similar to the general COVID population. Furthermore, HSCT recipients exhibit a protracted SARS-CoV-2 shedding, prolonging duration of symptoms and promoting the generation of highly mutated viruses. Last, most of studies report a higher COVID-19 mortality in HSCT recipients, mainly driven by age, comorbidities, time from transplantation, and immunosuppression because of both treatments and underlying hematological malignancy. Further studies are warranted to determine the proper impact of HSCT-related immune disorders on COVID-19 outcomes, and to evaluate specific treatments and vaccination strategy in this high-risk population. Taken together, those findings emphasize the need for more rigorous surveillance and preemptive measures for all HSCT recipients.
Identifiants
pubmed: 34813523
doi: 10.1097/MCC.0000000000000907
pii: 00075198-202202000-00010
pmc: PMC8711307
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
83-89Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Feng Y, Ling Y, Bai T, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med 2020; 201:1380–1388.
Belsky JA, Tullius BP, Lamb MG, et al. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect 2021; 82:329–338.
Mirouse A, Darmon M, Zafrani L, et al. Impact of immunosuppression on mortality in critically ill COVID-19 patients. Br J Haematol 2020; 191:394–395.
Passamonti F, Cattaneo C, Arcaini L, et al. ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020; 7:e737–e745.
ElGohary GM, Hashmi S, Styczynski J, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 2020; S1658-3876(20)30122-9. [Epub ahead of print].
Mushtaq MU, Shahzad M, Chaudhary SG, et al. Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients. Transplant Cell Ther 2021; 27:796e1–796e7.
Camargo JF, Mendoza MA, Lin R, et al. Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy. Transpl Infect Dis Off J Transplant Soc 2021; 23:e13625.
Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol 2021; 8:e185–e193.
Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest 2020; 130:6656–6667.
Varma A, Kosuri S, Ustun C, et al. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia 2020; 34:2809–2812.
Xhaard A, Xhaard C, D’Aveni M, et al. Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM-TC) multicentre cohort study. Br J Haematol 2021; 192:e121–e124.
El Fakih R, Haroon A, Alfraih F, et al. Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the Middle East. Bone Marrow Transplant 2021; 56:2144–2151.
COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med 2021; 47:60–73.
Elkrief A, Desilets A, Papneja N, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study. Eur J Cancer Oxf Engl 1990 2020; 139:181–187.
Kanellopoulos A, Ahmed MZ, Kishore B, et al. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience. Br J Haematol 2020; 190:e67–e70.
Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 2020; 383:2586–2588.
Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020; 383:2291–2293.
Lupo-Stanghellini MT, Xue E, Mastaglio S, et al. COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome. Bone Marrow Transplant 2021; 56:2312–2315.
Aguilar-Guisado M, Jiménez-Jambrina M, Espigado I, et al. Spanish Network for Research in Infectious Diseases. Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study. Clin Transplant 2011; 25:E629–E638.
Wang J, Zhou M, Xu J-Y, et al. Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: a systematic review and network meta-analysis. JAMA Netw Open 2020; 3:e2017652.
Song K, Gong H, Xu B, et al. Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID-19: a multicenter study. Cancer 2021; 127:437–448.
Liu H, Yang D, Chen X, et al. The effect of anticancer treatment on cancer patients with COVID-19: A systematic review and meta-analysis. Cancer Med 2021; 10:1043–1056.
Horby P, Lim WS, et al. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med 2020; 384:693–704.
Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 2020; 383:2603–2615.
Le Bourgeois A, Coste-Burel M, Guillaume T, et al. Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant. JAMA Netw Open 2021; 4:e2126344.
BMTCTN website [Internet]. [cited 28 September 2021]. Available at: https://web.emmes.com/study/bmt2/protocol/2101_protocol/2101_protocol.html .